Project Type(s):
Clinical Research
Principal Investigator(s):
To evaluate the efficacy of ZYN002 administered as a transdermal gel formulation, for up to 12 weeks, in patients ages 3 to <18 years, in the treatment of symptoms of Fragile X Syndrome (FXS).
Project Period:
December 1, 2019 — December 31, 2021
Funding Type(s):
Private company/industry
Funder(s):
Zynerba Pharmaceuticals
Zynerba Pharmaceuticals
Research Program(s):
Geographic Area(s):
National
Patient Population(s):
Adolescents, Children
Targeted Condition(s):
Autism Spectrum Disorder
